Browsing Tag
Lung cancer
47 posts
Dizal’s sunvozertinib beats chemo in phase 3 first-line NSCLC trial, opening path to new drug applications
Dizal's sunvozertinib beats platinum chemo in WU-KONG28 phase 3 first-line EGFR exon 20 NSCLC trial. What this means for patients, rivals and investors. Read more.
March 22, 2026
Can Freenome’s $1.1bn SPAC deal unlock a new chapter for blood-based multi-cancer detection?
Freenome merges with PCSC in $1.1B deal to go public as FRNM. Find out how its AI-powered blood tests could change early cancer detection.
December 7, 2025
Hyrnuo secures FDA approval as Bayer expands precision oncology in HER2-driven lung cancer
FDA approval of Bayer’s Hyrnuo opens a new targeted option for HER2-mutated lung cancer patients—find out how this therapy is reshaping precision oncology today.
November 20, 2025
Johnson & Johnson grabs RIPTAC cancer tech in $3bn Halda Therapeutics deal
Johnson & Johnson acquires Halda Therapeutics for $3.05B, expanding its oncology portfolio with precision prostate cancer treatments. Find out what’s next.
November 19, 2025
Investors watch Nuvalent ahead of pivotal neladalkib ALKOVE-1 topline data in resistant ALK-positive NSCLC
Nuvalent will unveil pivotal ALKOVE-1 data for neladalkib in TKI-pretreated ALK-positive NSCLC on November 17. Explore why investors believe this readout could redefine targeted lung cancer care.
November 15, 2025
Nuvalent (NASDAQ: NUVL) to release topline ALKOVE-1 trial data for neladalkib in advanced ALK-positive NSCLC on November 17
Nuvalent will present pivotal data for neladalkib in ALK-positive NSCLC on Nov 17. See what investors and analysts are expecting from ALKOVE-1.
November 15, 2025
N2OFF enters cancer-drug discovery market through MitoCareX merger
Find out how N2OFF’s merger with MitoCareX is reshaping its business and targeting pancreatic & lung cancers!
October 30, 2025
Pfizer data reveal sustained survival with BRAFTOVI + MEKTOVI in rare lung cancer subtype
Find out how Pfizer’s BRAFTOVI + MEKTOVI combination is redefining survival for BRAF V600E-mutant lung cancer and what it means for Pfizer’s oncology strategy.
October 19, 2025
Akeso advances cancer immunotherapy as Ivonescimab reaches Phase III milestone in lung cancer treatment
Akeso, Inc. (9926.HK) has completed patient enrollment for its pivotal Phase III trial (HARMONi-6), marking a significant step…
February 6, 2025
ImmunityBio, BeiGene launch Phase 3 Trial to advance lung cancer immunotherapy
ImmunityBio, Inc. (NASDAQ: IBRX) has entered into a collaboration and supply agreement with BeiGene, Ltd., a global oncology…
January 29, 2025